Published on: 2026-03-10
On Monday, March 9, 2026, HIMS stock closed at $22.16, up 40.79%, after Novo Nordisk ended its patent lawsuit and agreed to sell Wegovy and Ozempic on the Hims platform.
This development represents a strategic shift rather than a gradual change in valuation. The market perceived the news as not just legal relief; it offered HIMS a clearer and lower-risk path to remain within the GLP-1 category as regulators increase oversight of compounded alternatives.
The situation has changed. Investors are now asking whether this is a genuine turnaround or a temporary spike. This article examines the recent developments, potential risks, and key factors for traders to monitor.
Firstly, NVO is dropping its lawsuit tied to HIMS's marketing and sale of compounded semaglutide alternatives. However, NVO maintains the right to refile the lawsuit if it believes the agreement has been violated, which keeps a legal "snapback" risk in the background.
On the flip side, HIMS agreed to stop advertising compounded GLP-1 products and will instead offer FDA-approved versions of Wegovy and Ozempic through its platform, with availability expected later this month.
HIMS will provide branded medications in both oral and injectable forms, priced from $149 to $499 per month, depending on the specific product and plan structure.
The primary concern in recent months was that regulatory changes could outpace HIMS's ability to replace GLP-1 growth. This concern was well-founded.
The FDA has been steadily tightening its posture around compounded GLP-1s, including a wave of warning letters targeting telehealth firms over "false or misleading" claims about compounded obesity drugs.
Simultaneously, the FDA has announced that it has resolved the shortage of semaglutide injection products, which limits the circumstances under which large-scale compounding is generally permitted.
In this context, the partnership serves as a tactical measure to mitigate risk. While it does not ensure improved financial outcomes, it lowers the likelihood of an abrupt shutdown.
HIMS has responded to concerns about offering "copycat" versions of blockbuster drugs in a market with uncertain legal status.
NVO's decision to distribute through the platform signals confidence that the channel enables compliant delivery of branded medicines under the new regulations.
This is significant because trust is becoming central in the GLP-1 market. Patients need a prescriber, consistent supply, predictable dosing, and reliable pharmacovigilance.
HIMS had become a crowded short. MarketBeat estimated short interest of 81.01 million shares as of February 13, 2026, representing 43.24% of the public float, with about 1.7 days to cover based on average volume at the time.
When short interest is that elevated, a single headline that reduces existential risk can force rapid covering and create a reflexive spike.
HIMS' most recent results showed fast top-line growth and improving profitability:
2025 revenue: about $2.35 billion, up 59% year over year
2025 net income: $128 million
2025 adjusted EBITDA: $318 million
Subscribers: over 2.5 million
2026 revenue guidance: $2.7 billion to $2.9 billion
2026 adjusted EBITDA guidance: $300 million to $375 million
That relates because it means the stock was not rallying off nothing. It was rallying off a major risk reset on top of a company that is still growing.
It can, but it needs follow-through. A one-day rally is easy. A sustained comeback needs proof. Listed below are our three scenarios that could happen to HIMS stock next.
This is the scenario the stock is leaning toward after the spike.
HIMS converts high-intent demand into branded prescriptions at meaningful volume.
Marketing restrictions reduce regulatory friction, and the platform's health categories cross-sell effectively into weight loss patients.
The market rewards lower legal risk with a higher multiple, even if near-term margins compress.
This is the most common "headline reset" path.
Branded GLP-1 ramps, but pricing and margin trade-offs keep the market cautious.
The stock consolidates after an overbought technical reading, then trades earnings and guidance like a normal growth name again.
This is the scenario shorts will keep arguing.
Branded adoption is slower than the market expects, while compounded GLP-1 marketing restrictions reduce a key growth engine.
NVO keeps the right to refile, so any dispute over compliance can reintroduce headline risk.
The FDA continues aggressive enforcement actions, which raise compliance costs and limit product flexibility.
From a technical analysis perspective, HIMS stock just shifted from a steep downtrend to a sharp relief rally, and that usually produces choppy trading.
The technical dashboard showed RSI(14) at 80.378, which is firmly overbought, with "high volatility" via ATR readings.
| Level type | Level | Why it matters after a spike |
|---|---|---|
| RSI(14) | 80.378 |
Overbought conditions often invite profit-taking and mean reversion. |
| MA50 (simple) | $16.59 |
A gap back toward the $16 to $17 area would be a classic “mean reversion” risk in volatile growth names. |
| MA200 (simple) | $19.43 | A key trend reference that often becomes first support on a pullback. |
| Classic pivot | $22.11 | The first “decision” zone for consolidation after the news. |
| Classic support / resistance | $21.86 / $22.30 | These levels often define whether the market is absorbing supply or fading the move. |
Key Takeaway
The rally can remain constructive even if it consolidates, because the move was driven by a structural headline rather than a one-time beat.
The risk is that overbought momentum and crowded positioning can also produce sharp pullbacks when the next headline disappoints.
HIMS surged after NVO agreed to drop its lawsuit and distribute branded Wegovy and Ozempic through the HIMS platform.
Not necessarily. NVO is dropping the lawsuit as part of the agreement, but it retains the right to refile if it believes the deal terms are violated.
Under the new agreement, Hims will stop advertising compounded GLP-1s.
It can. GLP-1 access can support growth if customers accept pricing and the company maintains margins. Execution and legal clarity will matter most.
HIMS stock is volatile. It also has a history of sharp moves, especially when short interest is high. If you trade it, position size and defined risk levels matter more than prediction.
In conclusion, HIMS stock rallied, not only due to the NVO lawsuit headline, but also because of a new partnership. This partnership transitions HIMS from a high-friction, compounded GLP-1 approach to a branded distribution model as regulators increase enforcement on compounded obesity drugs.
The sustainability of this momentum depends on execution. HIMS must now scale branded GLP-1 product volume to replace the growth and economics of compounded products while maintaining its broader subscriber base.
Disclaimer: This material is for general information purposes only and is not intended as (and should not be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by EBC or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
